Apollomics presents vebreltinib data at AACR meeting

Apollomics presented two posters at the 2024 American Association for Cancer Research Annual Meeting, held April 5-10, 2024 in San Diego, Calif. “Vebreltinib’s selectivity and high in vivo potency against multiple tumor types in a variety of patient-derived tumor models demonstrate its potential to treat a variety of MET-altered tumors, as a single agent or in combination,” said Guo-Liang Yu, PhD, Chairman and Chief Executive Officer of Apollomics. “Based on preclinical models established from patients, we believe vebreltinib may also provide meaningful clinical benefit towards overcoming or preventing MET-amplification dependent resistance in EGFR-positive non-small cell lung cancer patients.” The first poster presented, titled, “Vebreltinib: A novel brain-penetrating MET kinase inhibitor demonstrates the mechanism of action and pharmacological anti-tumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levels,” demonstrated that vebreltinib is a novel potent and selective MET kinase inhibitor showing promising preclinical activity against patient-derived tumors from diverse organ sites and genomic alterations such as MET exon 14 skipping, MET fusion, MET amplification, or MET and hepatocyte growth factor over-expression at clinically relevant drug levels, providing proof-of-concepts for continued clinical development. The second poster presented, titled, “Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor,” demonstrated that adding vebreltinib to EGFR therapies overcomes MET-amplification dependent resistance with durable effect or prevents MET-dependent resistance to maximize therapeutic benefits.